Phase 2 Trial of GS-9973, a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia
Idelalisib is a first-in-class, selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and inhibits homing and retention of malignant B cells in lymphoid tissues. Furman and colleagues conducted a phase 3 trial that evaluated and compared the efficacy and safety of idelalisib plus rituximab (IDELA + R) and placebo plus rituximab (placebo + R).
Ibrutinib in Combination with Rituximab is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High-Risk Chronic Lymphocytic Leukemia: New, Updated Results of a Phase 2 Trial in 40 Patients
Based on phase 1/2 trials, single-agent ibrutinib induces an overall response rate (ORR) of 71% in relapsed chronic lymphocytic leukemia (CLL). To enhance responses to ibrutinib in patients with high-risk CLL, a phase 2 study of ibrutinib in combination with rituximab was conducted.
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed or Refractory CLL/SLL: Final Results of a Phase 1b Study
Single-Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses in Patients with Chronic Lymphocytic Leukemia with and without Deletion 17p
The Bruton’s Tyrosine Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in an Open-Label Extension Study
Bruton’s tyrosine kinase (BTK) plays a critical role in chronic lymphocytic leukemia (CLL) cell survival by modulating B-cell receptor signaling. Ibrutinib, a first-in-class oral inhibitor of BTK that was recently approved for use in mantle cell lymphoma, has been shown to inhibit proliferation, migration, and adhesion in CLL cells.
A Multicenter, Phase 4 Observational Study of Ofatumumab in Chronic Lymphocytic Leukemia: A European Research Initiative on CLL (ERIC) Study
In this observational, retrospective study that was conducted in Europe, the primary objective was to understand the safety profile of ofatumumab when it was administered outside of clinical trials to patients with previously treated chronic lymphocytic leukemia (CLL).
Ofatumumab + Chlorambucil versus Chlorambucil Alone in Patients with Untreated Chronic Lymphocytic Leukemia: Results of the Phase 3 Study Complement 1 (OMB110911)
Although chlorambucil (Clb) remains a standard option for elderly patients with chronic lymphocytic leukemia (CLL), more effective and tolerable treatment choices are needed. Compared with rituximab, ofatumumab (OF) demonstrated superior preclinical activity in CLL cells and has demonstrated clinical activity as monotherapy in patients with refractory CLL.
Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia
Eichhorst and colleagues conducted an international phase 3 study to evaluate the efficacy and tolerability of bendamustine and rituximab (BR) compared with fludarabine, cyclophosphamide, and rituximab (FCR) in first-line therapy of physically fit patients with chronic lymphocytic leukemia (CLL), who did not have a chromosome deletion 17p.
Safety and Efficacy of Obinutuzumab (GA101) with Fludarabine Cyclophosphamide or Bendamustine in the Initial Therapy of Patients with Chronic Lymphocytic Leukemia: Results from the Phase 1b GALTON Trial
Obinutuzumab is a novel, glycoengineered, type II CD20 monoclonal antibody designed to increase direct and antibody-dependent cellular cytotoxicity. Early phase 1/2 studies in patients with chronic lymphocytic leukemia (CLL) demonstrated single-agent activity with treatment-related neutropenia.
Page 2 of 4
Results 11 - 20 of 37
Results 11 - 20 of 37